ArticlePublic health genomics2018
Ethical, Legal, and Regulatory Issues for the Implementation of Omics-Based Risk Prediction of Women's Cancer: Points to Consider.
Article in Public health genomics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Implementation considerations for risk-tailored cancer screening in the population: A scoping review.Preventive medicine · 2024Article
- Article
- Article
- Barriers and Facilitators to the Implementation of a Personalized Breast Cancer Screening Program: Views of Spanish Health Professionals.International journal of environmental research and public health · 2022Article
- Article
- Exploring the Ethics of Implementation of Epigenomics Technologies in Cancer Screening: A Focus Group Study.Epigenetics insights · 2021Article
- Personalized early detection and prevention of breast cancer: ENVISION consensus statement.Nature reviews. Clinical oncology · 2020Review
- Ethical Issues in Research and Development of Epigenome-wide Technologies.Epigenetics insights · 2020Article
- DNA methylation aging clocks: challenges and recommendations.Genome biology · 2019Review
- Envisioning Implementation of a Personalized Approach in Breast Cancer Screening Programs: Stakeholder Perspectives.Healthcare policy = Politiques de sante · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveAdvances in omics open new opportunities for cancer risk prediction and risk-based screening interventions. However, implementation of risk prediction in clinical practice may impact the ethical, legal, and regulatory aspects of current cancer screening programs. In order to support decision-making, we analyzed the ethical, legal, and regulatory issues and developed a set of Points to Consider to support management of these issues.
methodsWe analyzed the legal and policy frameworks applicable to breast and cervical cancer screening programs in 7 European countries. We identified the most relevant issues to be considered, and we developed considerations for their management, based on the literature, the legal and policy frameworks, and our experience with similar issues.
resultsThe considerations focus on five topics: (A) health services planning, (B) information and invitation, (C) consent and data/sample collection, (D) risk calculation and communication of results, and (E) storage of data and residual samples.
conclusionCurrent frameworks might not be adequate to implement a risk prediction approach using omics factors due to the different characteristics of such approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.